Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified

• Published in: Zhongguo fei ai za zhi Vol. 18; no. 12; pp. 734 - 739
• Main Authors: Li, Xi, Qin, Na, Wang, Jinghui, Yang, Xinjie, Zhang, Xinyong, Lv, Jialin, Wu, Yuhua, Zhang, Hui, Nong, Jingying, Zhang, Quan, Zhang, Shucai
• Format: Journal Article
• Language: Chinese
• Published: China Chinese Anti-Cancer Association Chinese Antituberculosis Association 01.12.2015; Chinese Anti-Cancer Association; Chinese Antituberculosis Association
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - administration & dosage; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - metabolism; Carcinoma, Non-Small-Cell Lung - mortality; Chemotherapy; China; Crown Ethers - administration & dosage; Disease-Free Survival; EGFR mutation; Epidermal growth factor; Female; Humans; Icotinib hydrochloride; Lung cancer; Lung neoplasms; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - metabolism; Lung Neoplasms - mortality; Male; Middle Aged; Mutation; Quinazolines - administration & dosage; Receptor, Epidermal Growth Factor - genetics; Receptor, Epidermal Growth Factor - metabolism; Retrospective Studies; Treatment outcome; Tumors; Beijing China; Asia; China
• ISSN: 1009-3419; 1999-6187
• DOI: 10.3779/j.issn.1009-3419.2015.12.04

Icotinib is the first self-developed small molecular drug in China for targeted therapy of lung cancer. Compared to the other two commercially available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib, icotinib is similar to them in chemical structure, mechanism of activity and therapeutic effects. To explore the efficacy and side effects of icotinib hydrochloride in the treatment of the advanced non-small cell lung cancer (NSCLC) patients with EGFR mutation and wild-type. Patients with advanced NSCLC who were treated with icotinib hydrochloride in Beijing Chest Hospital were retrospective analyzed from March 2009 to December 2014. The clinical data of 124 patients (99 with EGFR mutation and 25 with wild type) with advanced NSCLC were enrolled in this study. The patients' overall objective response rate (ORR) was 51.6 % and the disease control rate (DCR) was 79.8%; The patients with EGFR mutation, ORR was 63.6%, DCR was 93.9%. The ORR was 4.0% and the DCR was 24.0%